BRCA1 and prostate carcinoma: FDA-approved PARPi (olaparib, niraparib, rucaparib, and talazoparib) are the first synthetic lethal targeted drugs to enter clinical practice and are currently used to treat ovarian, breast, pancreatic, or prostate cancer characterized by BRCA1/2 mutations [9].